valproic acid has been researched along with Glioma in 76 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid (VPA) inhibits histone deacetylase and has been reported to induce apoptosis in glioma." | 9.13 | Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. ( Driever, PH; Gnekow, A; Jorch, N; Kortmann, RD; Kramm, C; Pietsch, T; Rutkowski, S; Wolff, JE, 2008) |
| "The aim of this study was to investigate the impact of valproic acid (VPA) on survival and prognosis of patients with glioma who underwent postoperative radiotherapy." | 8.12 | Administration of Valproic Acid Improves the Survival of Patients with Glioma Treated with Postoperative Radiotherapy. ( Guan, S; Huang, B; Li, X; Sun, S; Wang, G; Yang, X, 2022) |
| "This study aimed at estimating the cumulative incidence of antiepileptic drug (AED) treatment failure of first-line monotherapy levetiracetam vs valproic acid in glioma patients with epilepsy." | 8.02 | First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid. ( Dirven, L; Fiocco, M; Koekkoek, JAF; Kouwenhoven, MCM; Taphoorn, MJB; van den Bent, MJ; van der Meer, PB; Vos, MJ, 2021) |
| " 1) VPA treatment clearly sensitized glioma cells to temozolomide: A protruding VPA-induced molecular feature in this context was the transcriptional upregulation/reexpression of numerous solute carrier (SLC) transporters that was also reflected by euchromatinization on the histone level and a reexpression of SLC transporters in human biopsy samples after VPA treatment." | 7.83 | Molecular dissection of the valproic acid effects on glioma cells. ( Hau, P; Herold-Mende, C; Hoja, S; Proescholdt, M; Rehli, M; Riemenschneider, MJ; Schulze, M, 2016) |
| " Epidermal growth factor receptor inhibitor gefitinib and valproic acid have been implicated in the treatment of malignancies including glioma involving autophagic and apoptotic mechanisms." | 7.81 | Valproic acid sensitizes human glioma cells to gefitinib-induced autophagy. ( Chang, CY; Chen, CJ; Chen, WY; Kuan, YH; Li, JR; Ou, YC; Wang, WY; Wu, CC, 2015) |
| "Valproic acid (VPA), an histone deacetylase inhibitor, is emerging as a promising therapeutic agent for the treatments of gliomas by virtue of its ability to reactivate the expression of epigenetically silenced genes." | 7.80 | Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid. ( Baronchelli, S; Biunno, I; Caldera, V; Cattaneo, M; Daga, A; Dalpra, L; DeBlasio, P; Mellai, M; Orlandi, R; Saccani, GJ; Schiffer, D, 2014) |
| "Temozolomide (TMZ) is given in addition to radiotherapy in glioma patients, but its interaction with the commonly prescribed antiepileptic drug valproic acid (VPA) is largely unknown." | 7.78 | Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. ( Lafleur, MV; Slotman, BJ; Sminia, P; Stalpers, LJ; Van den Berg, J; Van Nifterik, KA, 2012) |
| "The effects of valproic acid (VPA) on the viability, apoptosis, and invasiveness of two glioma cells (A172 and T98G) and the underlying mechanisms were studied." | 7.78 | Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms. ( Chen, Y; Tsai, YH; Tseng, SH, 2012) |
| "Temozolomide (TMZ) has become a key therapeutic agent in patients with malignant gliomas; however, its survival benefit remains unsatisfactory." | 7.78 | Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. ( Hou, Y; Jeong, CH; Jeun, SS; Kim, SM; Lim, JY; Park, KY; Ryu, CH; Woo, JS; Yoon, WS, 2012) |
| "Temozolomide (TMZ) is an oral alkylating agent that has been widely used in the treatment of refractory glioma, although inherent and acquired resistance to this drug is common." | 7.77 | Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation. ( Chang, YJ; Chen, CH; Chung, KT; Ku, MS; Yang, JT, 2011) |
| "C6 glioma cells were treated with clinically relevant concentrations of valproic acid (0." | 7.74 | Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells. ( Jawed, S; Kim, B; Niles, LP; Rincón Castro, LM, 2008) |
| "To determine the effects of chronic valproic acid sodium (VPA) treatment and subsequent withdrawal on the release of glutamate (Glu) and glutamine (Gln) by C6 glioma cells, so as to understand the role of Glu and Gln released by astrocytes in the antiepileptic mechanism of VPA and the rebound mechanism of VPA withdrawal." | 7.72 | [Effects of chronic valproic acid sodium treatment and withdrawal on glutamate and glutamine release of C6 glioma cells]. ( Gao, Y; Lei, LS; Wu, SG, 2003) |
| "Glioma is the most common primary malignant brain tumor in adults and the patients have poor prognosis despite treatment with surgery, radiotherapy and chemotherapy." | 6.66 | The therapeutic and neuroprotective effects of an antiepileptic drug valproic acid in glioma patients. ( Chen, H; Li, C; Sharma, A; Sharma, HS; Tan, Q; Xie, C; Zhan, W; Zhang, Z, 2020) |
| "Glioblastoma multiforme is the most common and aggressive primary brain tumor." | 6.48 | Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. ( Berendsen, S; Broekman, M; de Vos, F; Regli, L; Robe, P; Seute, T; Snijders, T; van Es, C, 2012) |
| "Luteolin has been detected to exert limited anti-tumor effects on gliomas, while valproic acid (VPA) is a common chemotherapy sensitizer in the treatment of tumors." | 5.62 | Valproic Acid Sensitizes Glioma Cells to Luteolin Through Induction of Apoptosis and Autophagy via Akt Signaling. ( Guan, W; Han, W; Wang, R; Yu, F; Zhi, F, 2021) |
| "Effective treatment of diffuse intrinsic pontine glioma (DIPG) remains a formidable challenge due to inadequate penetration of the blood-brain barrier (BBB) by systemically administered chemotherapies." | 5.62 | Clinical experience of convection-enhanced delivery (CED) of carboplatin and sodium valproate into the pons for the treatment of diffuse intrinsic pontine glioma (DIPG) in children and young adults after radiotherapy. ( Bienemann, A; Collins, P; Gill, S; Hollingworth, M; Hyare, H; Shankar, A; Szychot, E; Walker, D, 2021) |
| "Valproic acid (VPA) is a potent anti-epileptic and effective mood stabilizer." | 5.33 | Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells. ( Castro, LM; Gallant, M; Niles, LP, 2005) |
| "Valproic acid (VPA), which has demonstrated efficacy in the treatment of bipolar disorder, has been shown to alter components of the phosphoinositide (PI) signaling cascade and to increase gene expression mediated by the transcription factor activator protein 1 (AP-1)." | 5.32 | Effect of valproic acid on serotonin-2A receptor signaling in C6 glioma cells. ( Burke, T; Hensler, JG; Javors, M; Siafaka-Kapadai, A; Sullivan, NR, 2004) |
| "Valproic acid (VPA) is an anticonvulsant drug with demonstrated efficacy in the treatment of mania." | 5.29 | Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. ( Chen, G; Hawver, DB; Manji, HK; Potter, WZ; Wright, CB, 1996) |
| "Valproic acid (VPA) inhibits histone deacetylase and has been reported to induce apoptosis in glioma." | 5.13 | Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. ( Driever, PH; Gnekow, A; Jorch, N; Kortmann, RD; Kramm, C; Pietsch, T; Rutkowski, S; Wolff, JE, 2008) |
| " The present study investigated four common antiepileptic drugs, perampanel, carbamazepine (CBZ), sodium valproate (VPA) and levetiracetam (LEV), which are expected to have antitumor effects, and determined the most beneficial drug for the treatment of malignant glioma by comparing antitumor effects such as inhibition of cell proliferation and suppression of migration and invasion (using Transwell assays)." | 4.12 | Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells. ( Hanashima, Y; Hara, H; Katayama, Y; Ozawa, Y; Sano, E; Sumi, K; Tatsuoka, J; Yagi, C; Yamamuro, S; Yoshimura, S; Yoshino, A, 2022) |
| "The aim of this study was to investigate the impact of valproic acid (VPA) on survival and prognosis of patients with glioma who underwent postoperative radiotherapy." | 4.12 | Administration of Valproic Acid Improves the Survival of Patients with Glioma Treated with Postoperative Radiotherapy. ( Guan, S; Huang, B; Li, X; Sun, S; Wang, G; Yang, X, 2022) |
| "This study aimed at estimating the cumulative incidence of antiepileptic drug (AED) treatment failure of first-line monotherapy levetiracetam vs valproic acid in glioma patients with epilepsy." | 4.02 | First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid. ( Dirven, L; Fiocco, M; Koekkoek, JAF; Kouwenhoven, MCM; Taphoorn, MJB; van den Bent, MJ; van der Meer, PB; Vos, MJ, 2021) |
| " 1) VPA treatment clearly sensitized glioma cells to temozolomide: A protruding VPA-induced molecular feature in this context was the transcriptional upregulation/reexpression of numerous solute carrier (SLC) transporters that was also reflected by euchromatinization on the histone level and a reexpression of SLC transporters in human biopsy samples after VPA treatment." | 3.83 | Molecular dissection of the valproic acid effects on glioma cells. ( Hau, P; Herold-Mende, C; Hoja, S; Proescholdt, M; Rehli, M; Riemenschneider, MJ; Schulze, M, 2016) |
| " Epidermal growth factor receptor inhibitor gefitinib and valproic acid have been implicated in the treatment of malignancies including glioma involving autophagic and apoptotic mechanisms." | 3.81 | Valproic acid sensitizes human glioma cells to gefitinib-induced autophagy. ( Chang, CY; Chen, CJ; Chen, WY; Kuan, YH; Li, JR; Ou, YC; Wang, WY; Wu, CC, 2015) |
| "We report the case of an aborted awake craniotomy for a left frontotemporoinsular glioma due to ammonia encephalopathy on a patient taking Levetiracetam, valproic acid and clobazam." | 3.81 | Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy. ( Arroyo Pérez, R; Fernández-Candil, JL; León Jorba, A; Pacreu Terradas, S; Villalba Martínez, G; Vivanco-Hidalgo, RM, 2015) |
| "We found that VPA and TSA increase histone H4 acetylation in glioma cells, while chaetocin and BIX01294 at low concentrations reduce H3K9me3, and 3DZNep decreases H3K27me3." | 3.80 | The effects of selected inhibitors of histone modifying enzyme on C6 glioma cells. ( Kaminska, B; Maleszewska, M; Steranka, A, 2014) |
| "Valproic acid (VPA), an histone deacetylase inhibitor, is emerging as a promising therapeutic agent for the treatments of gliomas by virtue of its ability to reactivate the expression of epigenetically silenced genes." | 3.80 | Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid. ( Baronchelli, S; Biunno, I; Caldera, V; Cattaneo, M; Daga, A; Dalpra, L; DeBlasio, P; Mellai, M; Orlandi, R; Saccani, GJ; Schiffer, D, 2014) |
| "Temozolomide (TMZ) is given in addition to radiotherapy in glioma patients, but its interaction with the commonly prescribed antiepileptic drug valproic acid (VPA) is largely unknown." | 3.78 | Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. ( Lafleur, MV; Slotman, BJ; Sminia, P; Stalpers, LJ; Van den Berg, J; Van Nifterik, KA, 2012) |
| "The effects of valproic acid (VPA) on the viability, apoptosis, and invasiveness of two glioma cells (A172 and T98G) and the underlying mechanisms were studied." | 3.78 | Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms. ( Chen, Y; Tsai, YH; Tseng, SH, 2012) |
| "Temozolomide (TMZ) has become a key therapeutic agent in patients with malignant gliomas; however, its survival benefit remains unsatisfactory." | 3.78 | Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. ( Hou, Y; Jeong, CH; Jeun, SS; Kim, SM; Lim, JY; Park, KY; Ryu, CH; Woo, JS; Yoon, WS, 2012) |
| "Human glioma cell lines, T98-G, and SF295, were treated with temozolomide (TMZ) or irradiation (IR), with or without VPA (1." | 3.78 | Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro. ( Chen, FR; Chen, ZP; Li, C; Shao, CJ; Wu, MW; Xia, YF, 2012) |
| "Temozolomide (TMZ) is an oral alkylating agent that has been widely used in the treatment of refractory glioma, although inherent and acquired resistance to this drug is common." | 3.77 | Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation. ( Chang, YJ; Chen, CH; Chung, KT; Ku, MS; Yang, JT, 2011) |
| "The effects of the HDAC inhibitor valproic acid (VA) on postirradiation sensitivity in human glioma cell lines were evaluated using a clonogenic assay, exposing cells to VA up to 24 h after irradiation." | 3.74 | Postradiation sensitization of the histone deacetylase inhibitor valproic acid. ( Beam, K; Burgan, WE; Camphausen, K; Cerna, D; Chinnaiyan, P; Tofilon, PJ; Williams, ES, 2008) |
| "C6 glioma cells were treated with clinically relevant concentrations of valproic acid (0." | 3.74 | Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells. ( Jawed, S; Kim, B; Niles, LP; Rincón Castro, LM, 2008) |
| "A novel alkylating agent, temozolomide, has proven efficacious in the treatment of malignant gliomas." | 3.74 | O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies. ( Akagi, T; Aoyanagi, E; Kaneko, S; Sasai, K; Tabu, K; Tanaka, S, 2007) |
| "To determine the effects of chronic valproic acid sodium (VPA) treatment and subsequent withdrawal on the release of glutamate (Glu) and glutamine (Gln) by C6 glioma cells, so as to understand the role of Glu and Gln released by astrocytes in the antiepileptic mechanism of VPA and the rebound mechanism of VPA withdrawal." | 3.72 | [Effects of chronic valproic acid sodium treatment and withdrawal on glutamate and glutamine release of C6 glioma cells]. ( Gao, Y; Lei, LS; Wu, SG, 2003) |
| "When prescribed in association with a fotemustine-cisplatin regimen, VPA treatment results in a three-fold higher incidence of reversible thrombopenia, neutropenia or both." | 3.71 | Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. ( Bourg, V; Chichmanian, RM; Frenay, M; Lebrun, C; Thomas, P, 2001) |
| " In C6 glioma cells, endogenous ADP ribosylation was markedly increased by lithium chloride (+83%, P < 0." | 3.69 | Mood stabilizers have differential effects on endogenous ADP ribosylation in C6 glioma cells. ( Woods, CM; Young, LT, 1996) |
| "Direct cell counting and extent of [3H]thymidine incorporation demonstrated valproate to inhibit C6 glioma proliferation rate in a dose-dependent manner with a 1 mM concentration achieving 50% inhibition." | 3.68 | The anticonvulsant valproate teratogen restricts the glial cell cycle at a defined point in the mid-G1 phase. ( Martin, ML; Regan, CM, 1991) |
| "Glioma is the most common primary malignant brain tumor in adults and the patients have poor prognosis despite treatment with surgery, radiotherapy and chemotherapy." | 2.66 | The therapeutic and neuroprotective effects of an antiepileptic drug valproic acid in glioma patients. ( Chen, H; Li, C; Sharma, A; Sharma, HS; Tan, Q; Xie, C; Zhan, W; Zhang, Z, 2020) |
| "Glioblastoma multiforme is the most common and aggressive primary brain tumor." | 2.48 | Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. ( Berendsen, S; Broekman, M; de Vos, F; Regli, L; Robe, P; Seute, T; Snijders, T; van Es, C, 2012) |
| "Luteolin has been detected to exert limited anti-tumor effects on gliomas, while valproic acid (VPA) is a common chemotherapy sensitizer in the treatment of tumors." | 1.62 | Valproic Acid Sensitizes Glioma Cells to Luteolin Through Induction of Apoptosis and Autophagy via Akt Signaling. ( Guan, W; Han, W; Wang, R; Yu, F; Zhi, F, 2021) |
| "Effective treatment of diffuse intrinsic pontine glioma (DIPG) remains a formidable challenge due to inadequate penetration of the blood-brain barrier (BBB) by systemically administered chemotherapies." | 1.62 | Clinical experience of convection-enhanced delivery (CED) of carboplatin and sodium valproate into the pons for the treatment of diffuse intrinsic pontine glioma (DIPG) in children and young adults after radiotherapy. ( Bienemann, A; Collins, P; Gill, S; Hollingworth, M; Hyare, H; Shankar, A; Szychot, E; Walker, D, 2021) |
| "Therefore, HDACi treatment causes glioma cell entry into mitosis before DNA damage could be repaired and to the formation of an aberrant mitotic spindle that results in glioma cell death through mitotic catastrophe-induced apoptosis." | 1.40 | Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. ( Blasco-Angulo, N; Comella, JX; Cornago, M; Garcia-Alberich, C; Herreros, J; Llovera, M; Nager, M; Sanchis, D; Vall-Llaura, N, 2014) |
| "A currently studied experimental treatment for gliomas consists of intratumoral injection of oncolytic viruses (OV), such as oncolytic herpes simplex virus type 1 (oHSV)." | 1.39 | STAT3 activation promotes oncolytic HSV1 replication in glioma cells. ( Chiocca, EA; Haseley, A; Kaur, B; Meisen, H; Okemoto, K; Wagner, B, 2013) |
| "Although seizures in brain tumor patients are common, the knowledge on optimal anti-seizure therapy in this patient group is limited." | 1.35 | Efficacy of anti-epileptic drugs in patients with gliomas and seizures. ( Rijsman, RM; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2009) |
| "Valproic acid (VA) is a well-tolerated drug used to treat seizure disorders and has recently been shown to inhibit histone deacetylase (HDAC)." | 1.33 | Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. ( Burgan, WE; Camphausen, K; Cerna, D; Cerra, MA; Fine, H; Scott, T; Sproull, M; Tofilon, PJ, 2005) |
| "Valproic acid (VPA) is a potent anti-epileptic and effective mood stabilizer." | 1.33 | Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells. ( Castro, LM; Gallant, M; Niles, LP, 2005) |
| "Valproic acid (VPA), which has demonstrated efficacy in the treatment of bipolar disorder, has been shown to alter components of the phosphoinositide (PI) signaling cascade and to increase gene expression mediated by the transcription factor activator protein 1 (AP-1)." | 1.32 | Effect of valproic acid on serotonin-2A receptor signaling in C6 glioma cells. ( Burke, T; Hensler, JG; Javors, M; Siafaka-Kapadai, A; Sullivan, NR, 2004) |
| "Valproic acid (VPA) is a potent broad spectrum anticonvulsant with demonstrated efficacy in the treatment of Bipolar Affective Disorder, but the biochemical basis for VPA's antimanic or mood-stabilizing actions have not been fully elucidated." | 1.30 | Valproate robustly enhances AP-1 mediated gene expression. ( Chen, G; Huang, LD; Jiang, YM; Manji, HK; Yuan, PX, 1999) |
| "Valproic acid (VPA) is an anticonvulsant drug with demonstrated efficacy in the treatment of mania." | 1.29 | Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. ( Chen, G; Hawver, DB; Manji, HK; Potter, WZ; Wright, CB, 1996) |
| "Valproic acid (VPA) is a fatty acid antiepileptic with demonstrated antimanic properties, but the molecular mechanism or mechanisms underlying its therapeutic efficacy remain to be elucidated." | 1.29 | Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. ( Chen, G; Hawver, DB; Manji, HK; Potter, WZ; Wright, CB, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.63) | 18.7374 |
| 1990's | 12 (15.79) | 18.2507 |
| 2000's | 20 (26.32) | 29.6817 |
| 2010's | 29 (38.16) | 24.3611 |
| 2020's | 13 (17.11) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, ZY | 1 |
| Wang, XH | 1 |
| Wang, G | 1 |
| Guan, S | 1 |
| Yang, X | 1 |
| Sun, S | 1 |
| Huang, B | 1 |
| Li, X | 1 |
| van der Meer, PB | 3 |
| Dirven, L | 3 |
| Fiocco, M | 3 |
| Vos, MJ | 3 |
| Kouwenhoven, MCM | 3 |
| van den Bent, MJ | 3 |
| Taphoorn, MJB | 3 |
| Koekkoek, JAF | 3 |
| Yagi, C | 1 |
| Tatsuoka, J | 1 |
| Sano, E | 1 |
| Hanashima, Y | 1 |
| Ozawa, Y | 1 |
| Yoshimura, S | 1 |
| Yamamuro, S | 1 |
| Sumi, K | 1 |
| Hara, H | 1 |
| Katayama, Y | 1 |
| Yoshino, A | 1 |
| Hartung, EE | 1 |
| Mukhtar, SZ | 1 |
| Shah, SM | 1 |
| Niles, LP | 4 |
| Kuo, YJ | 1 |
| Yang, YH | 1 |
| Lee, IY | 1 |
| Chen, PC | 1 |
| Yang, JT | 2 |
| Wang, TC | 1 |
| Lin, MH | 1 |
| Yang, WH | 1 |
| Cheng, CY | 1 |
| Chen, KT | 1 |
| Huang, WC | 1 |
| Lee, MH | 1 |
| Han, W | 1 |
| Yu, F | 1 |
| Wang, R | 1 |
| Guan, W | 1 |
| Zhi, F | 1 |
| Li, C | 2 |
| Chen, H | 1 |
| Tan, Q | 1 |
| Xie, C | 1 |
| Zhan, W | 1 |
| Sharma, A | 1 |
| Sharma, HS | 1 |
| Zhang, Z | 1 |
| Park, SA | 1 |
| Han, HR | 1 |
| Ahn, S | 1 |
| Ryu, CH | 3 |
| Jeun, SS | 3 |
| Szychot, E | 1 |
| Walker, D | 1 |
| Collins, P | 1 |
| Hyare, H | 1 |
| Shankar, A | 1 |
| Bienemann, A | 1 |
| Hollingworth, M | 1 |
| Gill, S | 1 |
| Mezei, T | 1 |
| Mészáros, D | 1 |
| Pollner, P | 1 |
| Bagó, A | 1 |
| Fedorcsák, I | 1 |
| Banczerowski, P | 1 |
| Sipos, L | 1 |
| Raja, E | 1 |
| Komuro, A | 1 |
| Tanabe, R | 1 |
| Sakai, S | 1 |
| Ino, Y | 1 |
| Saito, N | 1 |
| Todo, T | 1 |
| Morikawa, M | 1 |
| Aburatani, H | 1 |
| Koinuma, D | 1 |
| Iwata, C | 1 |
| Miyazono, K | 1 |
| Killick-Cole, CL | 1 |
| Singleton, WGB | 1 |
| Bienemann, AS | 1 |
| Asby, DJ | 1 |
| Wyatt, MJ | 1 |
| Boulter, LJ | 1 |
| Barua, NU | 1 |
| Gill, SS | 1 |
| Bahna, SG | 1 |
| Laghari, AA | 1 |
| Ahmed, SI | 1 |
| Qadeer, N | 1 |
| Shamim, MS | 1 |
| Kapoor, S | 1 |
| Okemoto, K | 2 |
| Wagner, B | 1 |
| Meisen, H | 1 |
| Haseley, A | 1 |
| Kaur, B | 1 |
| Chiocca, EA | 3 |
| Stedt, H | 1 |
| Samaranayake, H | 1 |
| Pikkarainen, J | 1 |
| Määttä, AM | 1 |
| Alasaarela, L | 1 |
| Airenne, K | 1 |
| Ylä-Herttuala, S | 1 |
| Felix, FH | 1 |
| de Araujo, OL | 1 |
| da Trindade, KM | 1 |
| Trompieri, NM | 1 |
| Fontenele, JB | 1 |
| Cattaneo, M | 1 |
| Baronchelli, S | 1 |
| Schiffer, D | 1 |
| Mellai, M | 1 |
| Caldera, V | 1 |
| Saccani, GJ | 1 |
| Dalpra, L | 1 |
| Daga, A | 1 |
| Orlandi, R | 1 |
| DeBlasio, P | 1 |
| Biunno, I | 1 |
| Maleszewska, M | 1 |
| Steranka, A | 1 |
| Kaminska, B | 1 |
| Cornago, M | 1 |
| Garcia-Alberich, C | 1 |
| Blasco-Angulo, N | 1 |
| Vall-Llaura, N | 1 |
| Nager, M | 1 |
| Herreros, J | 1 |
| Comella, JX | 1 |
| Sanchis, D | 1 |
| Llovera, M | 1 |
| Villalba Martínez, G | 1 |
| Fernández-Candil, JL | 1 |
| Vivanco-Hidalgo, RM | 1 |
| Pacreu Terradas, S | 1 |
| León Jorba, A | 1 |
| Arroyo Pérez, R | 1 |
| Chang, CY | 1 |
| Li, JR | 1 |
| Wu, CC | 1 |
| Ou, YC | 1 |
| Chen, WY | 1 |
| Kuan, YH | 1 |
| Wang, WY | 1 |
| Chen, CJ | 1 |
| Nakashima, H | 1 |
| Kaufmann, JK | 1 |
| Wang, PY | 1 |
| Nguyen, T | 1 |
| Speranza, MC | 1 |
| Kasai, K | 2 |
| Otsuki, A | 2 |
| Nakano, I | 1 |
| Fernandez, S | 1 |
| Goins, WF | 1 |
| Grandi, P | 1 |
| Glorioso, JC | 1 |
| Lawler, S | 1 |
| Cripe, TP | 1 |
| Felix, F | 1 |
| Fontenele, J | 1 |
| Hoja, S | 1 |
| Schulze, M | 1 |
| Rehli, M | 1 |
| Proescholdt, M | 1 |
| Herold-Mende, C | 1 |
| Hau, P | 1 |
| Riemenschneider, MJ | 1 |
| Zhang, C | 1 |
| Liu, S | 1 |
| Yuan, X | 1 |
| Hu, Z | 1 |
| Li, H | 1 |
| Wu, M | 1 |
| Yuan, J | 1 |
| Zhao, Z | 1 |
| Su, J | 1 |
| Wang, X | 1 |
| Liao, Y | 1 |
| Liu, Q | 1 |
| Watanabe, S | 2 |
| Kuwabara, Y | 1 |
| Suehiro, S | 1 |
| Yamashita, D | 1 |
| Tanaka, M | 1 |
| Tanaka, A | 1 |
| Ohue, S | 1 |
| Araki, H | 1 |
| Kim, B | 1 |
| Rincón Castro, LM | 1 |
| Jawed, S | 1 |
| Wu, X | 1 |
| Chen, PS | 1 |
| Dallas, S | 1 |
| Wilson, B | 1 |
| Block, ML | 1 |
| Wang, CC | 1 |
| Kinyamu, H | 1 |
| Lu, N | 1 |
| Gao, X | 1 |
| Leng, Y | 1 |
| Chuang, DM | 1 |
| Zhang, W | 1 |
| Lu, RB | 1 |
| Hong, JS | 1 |
| Patel, A | 1 |
| Suzuki, M | 1 |
| Kurozumi, K | 1 |
| Saeki, Y | 1 |
| Wolff, JE | 1 |
| Kramm, C | 1 |
| Kortmann, RD | 1 |
| Pietsch, T | 1 |
| Rutkowski, S | 1 |
| Jorch, N | 1 |
| Gnekow, A | 1 |
| Driever, PH | 1 |
| Chinnaiyan, P | 1 |
| Cerna, D | 2 |
| Burgan, WE | 2 |
| Beam, K | 1 |
| Williams, ES | 1 |
| Camphausen, K | 2 |
| Tofilon, PJ | 2 |
| Benítez, JA | 1 |
| Arregui, L | 1 |
| Cabrera, G | 1 |
| Segovia, J | 1 |
| Oi, S | 1 |
| Natsume, A | 1 |
| Ito, M | 1 |
| Kondo, Y | 1 |
| Shimato, S | 1 |
| Maeda, Y | 1 |
| Saito, K | 1 |
| Wakabayashi, T | 1 |
| van Breemen, MS | 1 |
| Rijsman, RM | 1 |
| Taphoorn, MJ | 1 |
| Walchenbach, R | 1 |
| Zwinkels, H | 1 |
| Vecht, CJ | 1 |
| Fu, J | 1 |
| Shao, CJ | 2 |
| Chen, FR | 2 |
| Ng, HK | 1 |
| Chen, ZP | 2 |
| Chen, CH | 1 |
| Chang, YJ | 1 |
| Ku, MS | 1 |
| Chung, KT | 1 |
| Van Nifterik, KA | 1 |
| Van den Berg, J | 1 |
| Slotman, BJ | 1 |
| Lafleur, MV | 1 |
| Sminia, P | 1 |
| Stalpers, LJ | 1 |
| Singh, B | 1 |
| Boopathy, S | 1 |
| Somasundaram, K | 1 |
| Umapathy, S | 1 |
| Osuka, S | 1 |
| Takano, S | 1 |
| Ishikawa, E | 1 |
| Yamamoto, T | 1 |
| Matsumura, A | 1 |
| Park, KY | 2 |
| Kim, SM | 2 |
| Jeong, CH | 2 |
| Woo, JS | 2 |
| Hou, Y | 2 |
| Chen, Y | 1 |
| Tsai, YH | 1 |
| Tseng, SH | 1 |
| Berendsen, S | 1 |
| Broekman, M | 1 |
| Seute, T | 1 |
| Snijders, T | 1 |
| van Es, C | 1 |
| de Vos, F | 1 |
| Regli, L | 1 |
| Robe, P | 1 |
| Yoon, WS | 1 |
| Lim, JY | 1 |
| Wu, MW | 1 |
| Xia, YF | 1 |
| White, MC | 1 |
| Frampton, AR | 1 |
| Bacon, CL | 4 |
| Gallagher, HC | 2 |
| Haughey, JC | 1 |
| Regan, CM | 7 |
| Gao, Y | 2 |
| Lei, LS | 2 |
| Wu, SG | 2 |
| Sullivan, NR | 1 |
| Burke, T | 1 |
| Siafaka-Kapadai, A | 1 |
| Javors, M | 1 |
| Hensler, JG | 1 |
| Scott, T | 1 |
| Sproull, M | 1 |
| Cerra, MA | 1 |
| Fine, H | 1 |
| Castro, LM | 1 |
| Gallant, M | 1 |
| Lai, JS | 1 |
| Zhao, C | 1 |
| Warsh, JJ | 1 |
| Li, PP | 1 |
| Dmytriyev, A | 1 |
| Tkach, V | 1 |
| Rudenko, O | 1 |
| Bock, E | 2 |
| Berezin, V | 2 |
| Sasai, K | 1 |
| Akagi, T | 1 |
| Aoyanagi, E | 1 |
| Tabu, K | 1 |
| Kaneko, S | 1 |
| Tanaka, S | 1 |
| Wang, AD | 1 |
| Ji, XY | 1 |
| Huang, Q | 1 |
| Wang, CR | 1 |
| Dong, J | 1 |
| Lan, Q | 1 |
| Chen, G | 5 |
| Manji, HK | 5 |
| Hawver, DB | 3 |
| Wright, CB | 2 |
| Potter, WZ | 4 |
| Young, LT | 1 |
| Woods, CM | 1 |
| Yamaji, T | 1 |
| Kagaya, A | 1 |
| Uchitomi, Y | 1 |
| Yokata, N | 1 |
| Yamawaki, S | 1 |
| Hsiao, JK | 1 |
| Risby, ED | 1 |
| Masana, MI | 1 |
| Yuan, P | 1 |
| O'Driscoll, E | 2 |
| Ständer, M | 1 |
| Dichgans, J | 1 |
| Weller, M | 1 |
| Bojic, U | 1 |
| Ehlers, K | 1 |
| Ellerbeck, U | 1 |
| O'Connell, C | 1 |
| Kawa, A | 1 |
| Lepekhin, E | 1 |
| Nau, H | 1 |
| Arroyo, S | 1 |
| Rumiá, J | 1 |
| Martínez, I | 1 |
| Ribalta, T | 1 |
| Yuan, PX | 1 |
| Jiang, YM | 1 |
| Huang, LD | 1 |
| O'Leary, G | 1 |
| Odumeru, O | 1 |
| Fagan, C | 1 |
| Fitzpatrick, T | 1 |
| Moriarty, DC | 1 |
| Bourg, V | 1 |
| Lebrun, C | 1 |
| Chichmanian, RM | 1 |
| Thomas, P | 1 |
| Frenay, M | 1 |
| Martin, ML | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study on Glioma Patients: Understanding Their Glioma Clinical Trial Experiences[NCT05958472] | 500 participants (Anticipated) | Observational | 2024-08-31 | Not yet recruiting | |||
| Valproic Acid for Children With Recurrent and Progressive Brain Tumors[NCT01861990] | Phase 1 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to Feasibility of the trial was proven to be absent.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for valproic acid and Glioma
| Article | Year |
|---|---|
The therapeutic and neuroprotective effects of an antiepileptic drug valproic acid in glioma patients.
Topics: Anticonvulsants; Brain Neoplasms; Glioma; Humans; Neuroprotective Agents; Valproic Acid | 2020 |
Choice of therapeutic anti-seizure medication in patients with brain tumour.
Topics: Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Epilepsy; Gabapentin; Glioma; Humans; L | 2019 |
Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy | 2012 |
Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy.
Topics: Adenylyl Cyclases; Animals; Bipolar Disorder; Carbamazepine; Cell Line; Glioma; GTP-Binding Proteins | 1996 |
1 trial available for valproic acid and Glioma
| Article | Year |
|---|---|
Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma.
Topics: Adolescent; Brain Neoplasms; Child; Child, Preschool; Enzyme Inhibitors; Female; Follow-Up Studies; | 2008 |
71 other studies available for valproic acid and Glioma
| Article | Year |
|---|---|
Valproic Acid Inhibits Glioma and Its Mechanisms.
Topics: Brain Neoplasms; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Glioma; Humans; Valproic Acid | 2022 |
Administration of Valproic Acid Improves the Survival of Patients with Glioma Treated with Postoperative Radiotherapy.
Topics: Brain Neoplasms; Glioma; Humans; Kaplan-Meier Estimate; Prognosis; Retrospective Studies; Survival R | 2022 |
Effectiveness of Antiseizure Medication Duotherapies in Patients With Glioma: A Multicenter Observational Cohort Study.
Topics: Anticonvulsants; Cohort Studies; Glioma; Humans; Levetiracetam; Piracetam; Retrospective Studies; Se | 2022 |
Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells.
Topics: Anticonvulsants; Cadherins; Carbamazepine; Glioma; Humans; Levetiracetam; Matrix Metalloproteinase 2 | 2022 |
Effectiveness of Antiseizure Medication Triple Therapy in Patients With Glioma With Refractory Epilepsy: An Observational Cohort Study.
Topics: Anticonvulsants; Drug Resistant Epilepsy; Epilepsy, Generalized; Glioma; Humans; Retrospective Studi | 2023 |
5-Azacytidine upregulates melatonin MT
Topics: Animals; Azacitidine; Cell Line; Cell Line, Tumor; Epigenesis, Genetic; Gene Expression; Gene Expres | 2020 |
Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide: A nationwide population-based cohort study in Taiwan.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Enzyme Inhibitors; Fema | 2020 |
Valproic Acid Sensitizes Glioma Cells to Luteolin Through Induction of Apoptosis and Autophagy via Akt Signaling.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Glioma; Huma | 2021 |
Combination treatment with VPA and MSCs‑TRAIL could increase anti‑tumor effects against intracranial glioma.
Topics: Adenoviridae; Animals; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Ce | 2021 |
Clinical experience of convection-enhanced delivery (CED) of carboplatin and sodium valproate into the pons for the treatment of diffuse intrinsic pontine glioma (DIPG) in children and young adults after radiotherapy.
Topics: Antineoplastic Agents; Carboplatin; Child; Convection; Diffuse Intrinsic Pontine Glioma; Glioma; Hum | 2021 |
First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Female; Glioma; Humans; Levetiracetam; Male; Middle Aged; R | 2021 |
Supplementary valproate therapy for glioma patients: An alternative opportunity to enhance the efficiency of radio-chemotherapy
Topics: Glioma; Humans; Hungary; Prognosis; Retrospective Studies; Valproic Acid | 2021 |
Bone morphogenetic protein signaling mediated by ALK-2 and DLX2 regulates apoptosis in glioma-initiating cells.
Topics: Activin Receptors, Type I; Animals; Apoptosis; Bone Morphogenetic Proteins; Brain Neoplasms; Cell Di | 2017 |
Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma.
Topics: Acetylation; Adjuvants, Pharmaceutic; Animals; Anticonvulsants; Apoptosis; Brain Stem Neoplasms; Cel | 2017 |
Epigenetic induction of melatonin MT
Topics: Animals; Anticonvulsants; Cell Line, Tumor; Chromatin Immunoprecipitation; CREB-Binding Protein; Dos | 2017 |
Valproic acid and its inhibition of tumor growth in systemic malignancies: beyond gliomas.
Topics: Anticonvulsants; Apoptosis; Brain Neoplasms; Cell Movement; Glioma; Humans; Valproic Acid | 2013 |
STAT3 activation promotes oncolytic HSV1 replication in glioma cells.
Topics: Anticonvulsants; Blotting, Western; Brain Neoplasms; Cell Proliferation; Combined Modality Therapy; | 2013 |
Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Antiviral Agents; Combined Modality | 2013 |
Retrospective evaluation of the outcomes of children with diffuse intrinsic pontine glioma treated with radiochemotherapy and valproic acid in a single center.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Carboplatin; Child; Child, Preschool; Femal | 2014 |
Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Endopl | 2014 |
The effects of selected inhibitors of histone modifying enzyme on C6 glioma cells.
Topics: Acetylation; Adenosine; Animals; Azepines; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme | 2014 |
Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe.
Topics: Apoptosis; Cell Cycle Proteins; Cell Death; Cell Survival; Checkpoint Kinase 1; G2 Phase Cell Cycle | 2014 |
Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy.
Topics: Anesthesia, General; Anesthesia, Local; Anticonvulsants; Aphasia; Benzodiazepines; Brain Diseases; B | 2015 |
Valproic acid sensitizes human glioma cells to gefitinib-induced autophagy.
Topics: Adenylate Kinase; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; | 2015 |
Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.
Topics: Acetylation; Acetyltransferases; Anilides; Brain Neoplasms; Capsid; Cell Line, Tumor; Cell Nucleus; | 2015 |
Valproic Acid May Be Tested in Patients With H3F3A-Mutated High-Grade Gliomas.
Topics: Brain Neoplasms; Glioma; Humans; Mutation; Valproic Acid | 2016 |
Molecular dissection of the valproic acid effects on glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Dacarbazine; Decision Support Syst | 2016 |
Valproic Acid Promotes Human Glioma U87 Cells Apoptosis and Inhibits Glycogen Synthase Kinase-3β Through ERK/Akt Signaling.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Enzyme Activation; Extracellular Signal-Regulated MAP | 2016 |
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2017 |
Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epi | 2008 |
Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons.
Topics: Animals; Astrocytes; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cerebral C | 2008 |
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Butyrates; Drug Synergism; Drug Therapy, Combinatio | 2008 |
Postradiation sensitization of the histone deacetylase inhibitor valproic acid.
Topics: Brain Neoplasms; Cell Line, Tumor; Enzyme Inhibitors; Glioma; Histone Deacetylase Inhibitors; Humans | 2008 |
Valproic acid induces polarization, neuronal-like differentiation of a subpopulation of C6 glioma cells and selectively regulates transgene expression.
Topics: Animals; beta-Galactosidase; Bromodeoxyuridine; Cell Death; Cell Differentiation; Cell Line, Tumor; | 2008 |
Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells.
Topics: Antigens, Neoplasm; Azacitidine; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Decitabine; D | 2009 |
Efficacy of anti-epileptic drugs in patients with gliomas and seizures.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Carbamazepine; Drug Therapy, Combination; Female; Follow-Up | 2009 |
Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines.
Topics: Animals; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cel | 2010 |
Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Synergism; Glioma; | 2011 |
Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine | 2012 |
Fourier transform infrared microspectroscopy identifies protein propionylation in histone deacetylase inhibitor treated glioma cells.
Topics: Acetylation; Cell Line, Tumor; Coenzyme A Ligases; Drug Evaluation, Preclinical; Glioma; Histone Dea | 2012 |
Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain.
Topics: Angiogenesis Inhibitors; Animals; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Cell Line | 2012 |
Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Bystander Effect; Cell Line, Tumor; Connexins; Genetic Therapy; | 2012 |
Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms.
Topics: Anticonvulsants; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Movement; Flow Cytometry; Gliom | 2012 |
Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enz | 2012 |
Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; Flow Cytometry; Glioma; | 2012 |
The histone deacetylase inhibitor valproic acid enhances equine herpesvirus type 1 (EHV-1)-mediated oncolysis of human glioma cells.
Topics: Animals; Brain Neoplasms; Genetic Vectors; Glioma; Herpesvirus 1, Equid; Histone Deacetylase Inhibit | 2013 |
Antiproliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phase.
Topics: Active Transport, Cell Nucleus; Animals; Anticonvulsants; Cell Cycle; Cell Cycle Proteins; Cell Divi | 2002 |
[Changes in GAT-3 and GABA-T mRNA expression of C6 glioma cells in response to a 2-week treatment with sodium valproate and withdrawal].
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Cell Line, Tumor; GABA Plasma Membrane Trans | 2003 |
[Effects of chronic valproic acid sodium treatment and withdrawal on glutamate and glutamine release of C6 glioma cells].
Topics: Anticonvulsants; Glioma; Glutamic Acid; Glutamine; Humans; Time Factors; Tumor Cells, Cultured; Valp | 2003 |
Effect of valproic acid on serotonin-2A receptor signaling in C6 glioma cells.
Topics: Animals; Anticonvulsants; Binding Sites; Cell Line; Dose-Response Relationship, Drug; Glioma; Ketans | 2004 |
Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.
Topics: Acetylation; Animals; Brain Neoplasms; Cell Death; Cell Proliferation; Disease Progression; DNA Repa | 2005 |
Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells.
Topics: Animals; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Dose-Response Relationship, Drug; | 2005 |
Cytoprotection by lithium and valproate varies between cell types and cellular stresses.
Topics: Antimanic Agents; Caspase 3; Caspases; Cell Death; Cell Line, Tumor; Cytochromes c; Cytoprotection; | 2006 |
An automatic procedure for evaluation of single cell motility.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Movement; Enzyme Inhibitors; Fibroblasts; Glioma; Gr | 2006 |
O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Astrocytes; Cell Division; Dacarbazine; DNA Modification | 2007 |
[Studies on the target cells and molecules with sodium valproate induced differential of human glioma cells].
Topics: AC133 Antigen; Actins; Animals; Antigens, CD; Brain Neoplasms; Cell Differentiation; Flow Cytometry; | 2007 |
Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro.
Topics: Animals; Blotting, Western; Cell Membrane; Cytosol; Diglycerides; Glioma; Isoenzymes; Kinetics; Phor | 1994 |
Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells.
Topics: Adenylyl Cyclases; Animals; Brain Neoplasms; Glioma; GTP-Binding Proteins; Radioligand Assay; Rats; | 1996 |
Mood stabilizers have differential effects on endogenous ADP ribosylation in C6 glioma cells.
Topics: Adenosine Diphosphate Ribose; Animals; Carbamazepine; Glioma; Lithium Chloride; Rats; Tumor Cells, C | 1996 |
Effects of carbamazepine and sodium valproate on 5-HT-induced calcium increase in individual C6 rat glioma cells.
Topics: Animals; Calcium; Carbamazepine; Cells, Cultured; Glioma; Rats; Serotonin; Valproic Acid | 1996 |
Increase in AP-1 transcription factor DNA binding activity by valproic acid.
Topics: Activating Transcription Factor 2; Animals; Anticonvulsants; Brain; Cyclic AMP Response Element-Bind | 1997 |
Valproic acid suppresses G1 phase-dependent sialylation of a 65kDa glycoprotein in the C6 glioma cell cycle.
Topics: Depression, Chemical; Enzyme Inhibitors; G1 Phase; Glioma; Glycoproteins; Humans; Molecular Weight; | 1997 |
Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells.
Topics: Anticonvulsants; Antineoplastic Agents; Carbamazepine; Cell Division; Cell Survival; Glioma; Humans; | 1998 |
Studies on the teratogen pharmacophore of valproic acid analogues: evidence of interactions at a hydrophobic centre.
Topics: Animals; Cell Differentiation; Cell Division; Dose-Response Relationship, Drug; Female; Glioma; Male | 1998 |
[Drug-resistant epilepsy].
Topics: Adult; Anticonvulsants; Brain Neoplasms; Calcinosis; Carbamazepine; Diagnosis, Differential; Drug Re | 1998 |
Valproate robustly enhances AP-1 mediated gene expression.
Topics: Animals; Anticonvulsants; Bipolar Disorder; DNA-Binding Proteins; Gene Expression Regulation; Genes, | 1999 |
Antiproliferative actions of inhalational anesthetics: comparisons to the valproate teratogen.
Topics: Anesthetics, Inhalation; Animals; Blotting, Western; Cell Division; Dimethyl Sulfoxide; Enflurane; F | 2000 |
Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispl | 2001 |
The anticonvulsant valproate teratogen restricts the glial cell cycle at a defined point in the mid-G1 phase.
Topics: Animals; Cell Cycle; Cell Division; Cell Line; Cell Survival; DNA Replication; G1 Phase; Glioma; Kin | 1991 |
The anticonvulsant sodium valproate specifically induces the expression of a rat glial heat shock protein which is identified as the collagen type IV receptor.
Topics: Anticonvulsants; Astrocytes; Cell Adhesion; Cells, Cultured; Chromatography, Affinity; Glioma; Heat- | 1988 |
Therapeutic levels of sodium valproate inhibit mitotic indices in cells of neural origin.
Topics: Animals; Cell Adhesion; Cell Differentiation; Cell Line; Dose-Response Relationship, Drug; Glioma; M | 1985 |